gp100 209-217 mutant (HLA-A*02:01) 210M

gp100 209-217 mutant (HLA-A*02:01) 210M
€50.00 *

Prices plus VAT plus shipping costs

Delivery time 3 weeks
sterile and endotoxin free Delivery Format:
The product is supplied freeze dried as trifluoracetate salt

Amount in mg:

make your choice

  • EP07926_1
gp100 209-217 Pos. 210M (HLA-A*02:01) IMDQVPFSV is a linear peptidic epitope studied as part of... more
Product information "gp100 209-217 mutant (HLA-A*02:01) 210M"
gp100 209-217 Pos. 210M (HLA-A*02:01) IMDQVPFSV is a linear peptidic epitope studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human). This epitope has been studied for immune reactivity in several publication, tested in T cell assays and MHC ligand assays. This modified gp100 peptide amino acids 209 to 217 is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. Alteration of the gp100 209-217 peptide to gp100 209-217 Met2 at the second amino acid changing threonine to a methionine was found to increase the affinity for MHC-associated HLA-A2.1 resulting in enhanced induction of T cells reactive to native gp100

 
Sequence:IMDQVPFSV
Gene:PMEL
Delivery: 3 weeks
C-Terminus:NH2
N-Terminus:H
Purity:95%
Amount:1 mg
Counter Ion:TFA
Protein:Melanocyte protein PMEL
Species:Human
Allele:HLA-A*02:01
Application :T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication :Cancer, Epithelium, Melanoma
Dokumente - Protokolle - Downloads more
Viewed